Recently, local chemotherapy by percutaneous drug delivery has attracted renewed interest from the standpoint of optimization of drug delivery." Topical application should concentrate the drug in the tissues to which it is applied and diminish the drug concentration in other tissues and blood. It could also minimize the side effect of gastrointestinal damage and the first-pass effect observed in the case of oral administration.2) Flurbiprofen (FP) is an orally active, nonsteroidal anti-inflammatory drug found to be effective in the treatment of rheumatoid arthritis, but its side effect of gastrointestinal damage has limited its utilization.3) Therefore, topical application of FP warrants investigation as an alternative to oral treatment. However, it is well-known that most drugs can not penetrate the skin readily, and many factors may influence the skin penetration.4) In this context, we have reported that a rise of skin surface temperature could increase the transdermal absorption of methyl salicylate from a cataplasm. 5) In the present study, transdermal absorption characteristics of FP from a cataplasm at various skin temperatures were investigated with both in vitro and in vivo techniques. In addition, the anti-inflammatory effects at various skin temperatures were evaluated.
Experimental

Materials
FP was obtained commercially (Nippon Zanbon Co., Ltd., Tokyo, Japan) and used without further purification. Styrene isoprene block copolymer was also obtained commercially (Kimura Industry Co., Ltd., Tokyo, Japan). All other chemicals were of reagent grade.
Preparation of a Cataplasm of FP A cataplasm (CFP) containing FP was prepared by Sansho Pharmaceutical Co., Ltd. (Saitama, Japan). 'The formulation contains FP (2 mg), olive oil (115 mg), styrene isoprene block copolymer (78 mg) and other minor constituents (19 mg) in 14 cm2. The CFP has a water-absorbent resin sheet on the drug reservoir phase to cool the skin surface. The structure of the cataplasm is shown in Fig. 1 . CFP containing no FP was prepared to evaluate the net effect of cooling on inflammation.
Control of Skin Surface Temperature In the in vivo absorption and the anti-inflammatory experiments, the skin surface temperature after CFP application was controlled by the following treatments. Condition A: A polyvinyl bag containing ice-water was put on the CFP. Condition B: Water was added to a water-absorbent resin sheet of the CFP. Condition C: No treatment was carried out. Condition D: A chemical warmer (Hakugen Co., Ltd., Tokyo, Japan) was put on the CFP. In the anti-inflammatory experiment, condition D' was used instead of condition D; in this case, the rat foot on which the CFP was applied was wrapped with a polyvinyl bag and placed in a water bath at 41°C.
By manual monitoring during each treatment, the skin temperature could be maintained within a narrow range, as shown in Table I . The skin surface temperature was measured with a thermometer having a platinum resistance sensor (model EH200-06, Chino Works. Ltd., Tokyo, Japan) during experiments.
In Vivo Transdermal Absorption Experiment Male Wistar albino rats weighing 250-300 g, whose abdominal hair was removed with animal clippers and a shaver at 24 h before the experiment, were used under anesthesia with pentobarbital, given intraperitoneally. CFP (available area; 14 cm2) covered with a protective peel liner was applied on the abdominal skin, and treatment A, B, C or D was employed for controlling the skin temperature. After the temperature had reached a constant level, the liner was removed from the CFP to start the absorption experiment. Blood samples were collected from the jugular vein at fixed intervals. A mixture of 0.2 ml of plasma and 0.2 ml of Me0H was shaken and centrifuged, and FP in the supernatant was determined by HPLC.
Intravenous Administration Experiment A polyethylene glycol solution of FP (2.5 mg/ml) was injected into the femoral vein of three rats weighing 250-300 g (dose; 500 pg/head), and the plasma concentration of FP was determined by high performance liquid chromatography (HPLC) at fixed intervals. The mean plasma levels of FP (Cr) versus time obeyed biexponential kinetics as represented by Eq. 1.
(1)
Release and in Vitro, Penetration Experiments
A diffusion cell similar to that reported by Loftsson and Bodor,6) was used for the release and in vitro penetration experiments. It has a 6.8 cm' donor area and a49 ml receptor volume. Cellulose membranes (pore size 24 A, Visking Co., Ltd., U.S.A) were used as diffusion membranes for the release experiment. The full-thickness abdominal skin excised from a rat weighing 250-300 g, whose hair had been removed as in the in vivo experiment, was used for the in vitro penetration experiment. The diffusion cell and receptor medium, isotonic sodium phosphate-buffered saline (pH 7.4) containing kanamycin sulfate (100 ppm), were placed in a thermostated chamber at least 10 h before the experiment, in which the temperature was regulated at the mean of each in vivo experiment. Just before the experiment, the excised skin or cellulose membrane was mounted in the diffusion cell, the receptor phase was filled with the medium, and finally the CFP was applied on the skin or membrane surface of the donor side. The receptor phase was stirred with a magnetic stirrer covered with an adiabator 1, Rayon-polyester coverstrip; 2, water-absorbent resin sheet; 3, polyester-unwoven textile, the upper side of which is laminated with polyethylene; 4, drug reservoir; 5, protective peel liner. 
Results
In Vivo Transdermal Absorption Experiment Figure 2 shows the plasma concentration of FP after application of the CFP on the rat abdomen under conditions A, B, C and D. As the skin temperature was raised, the plasma concentration of FP increased significantly. Under all conditions except for D, the plasma levels increased initially and thereafter a nearly constant level was maintained .
Release and in Vitro Penetration Experiments
The release of FP from CFP is illustrated in Fig. 3 . The release was very fast under all conditions and the recoveries in 3 h were higher than 70% of the initial content. Figure 4 represents the penetration of FP through an excised rat skin . The penetration of FP was relatively slow and the recoveries were somewhat low in comparison with release from the CFP. The release and penetration were both greatly enhanced by a rise of skin temperature .
Absorption Behavior Estimated by Deconvolution
Since it is difficult to measure the transdermal absorption behavior of FP experimentally, it was estimated by a deconvolution method as described in the experimental section. The time course of absorbed FP thus obtained (% of initial content) is shown in Fig. 5 . The absorption of FP was greatly enhanced by a rise of temperature and it was found that the flux under condition D was about 4 times higher than that under condition A. Skin Accumulation Figure 6 shows the skin accumulation of FP at 10 h in the in vivo and in vitro experiments. A tendency for skin accumulation of FP to decrease with a rise of skin temperature was observed in the in vivo experiment, but not in the in vitro experiment.
Anti-inflammatory Effect
Anti-inflammatory effects of CFP at various skin temperatures are shown in Fig. 7 . The effect was evaluated in terms of the suppressive effect on the swelling edema in the foot of rats produced by a strong blow. The edema was suppressed significantly under condition C and especially under cooling conditions A and B, but no effect was found under warming condition D'. Figure 8 shows the anti-inflammatory effect of temperature when CFP containing no FP was applied. The application under cooling conditions (A and B) suppressed the swelling significantly.
Discussion
In the present investigation, the in vivo and in vitro transdermal absorption and pharmacological effect of FP in the CFP were examined under various temperature conditions. A rise of skin temperature resulted in an increase of the FP plasma concentration (Fig. 2) , as in the case of salicylic acid,9) carbinoxamine9) and methyl salicylate.5) Moreover, the release (Fig. 3 ) and skin penetration (Fig. 4 ) of FP were also enhanced with a rise of temperature.
Release data (Fig. 3) were analyzed by the use of Eq. 2:
where A is the amount of FP appearing in the receptor phase, F is the available fraction of the applied dose (A0) and kr is a release rate constant. On the other hand, penetration data were analyzed by the use of Eq. 3 in which a lag time was taken into consideration, based on the experimental data in Fig. 4 :
where kp is a penetration rate constant and t is a lag time. Furthermore, the deconvolution data were analyzed by the use of Eq. 2 using ka (absorption rate constant) instead of k1, where A is the absorbed amount of FP, since the lag times were practically not recognized in Fig. 5 . The values of parameters involved in the equations are presented in Table II. Our findings  from Table II 
